University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.
Allergy. 2012 Jun;67(6):822-30. doi: 10.1111/j.1398-9995.2012.02817.x. Epub 2012 Apr 3.
There is no in vitro test to predict the induction of long-term tolerance in patients treated with venom immunotherapy (VIT). The aim of this study was to investigate whether immunotherapy-induced changes in basophil responsiveness reflect a state of protection and the induction of a tolerance.
Twenty-three patients with allergic reaction after Hymenoptera sting (11 wasp and 12 honeybee) were treated with VIT. In all patients, a CD63 basophil activation test was performed before the beginning of immunotherapy, after 1 year and after completing 4-6.5 years of immunotherapy (approximately 1 year after stopping). The tolerance was then evaluated by a sting challenge test. The basophil activation test was repeated 3-6 months after the challenge.
Twenty-two subjects showed a negative sting challenge, and one subject, a positive sting challenge. Allergen-specific basophil response remained unchanged after 1 year of immunotherapy. However, after immunotherapy, a significant and approximately fourfold decrease was demonstrated in all tolerant subjects mainly in response to submaximal 0.1 μg/ml allergen concentration. This depression was sustained and did not change with the sting challenge test. In a nontolerant patient with a positive sting challenge, basophil response did not change.
Our results suggest that the depression of allergen-specific basophil response seems to be associated with the induction of a tolerance after completing a course of VIT.
目前尚无体外检测方法可预测接受毒液免疫治疗(VIT)的患者产生长期耐受的情况。本研究旨在探讨免疫治疗诱导的嗜碱性粒细胞反应变化是否反映了一种保护状态和诱导耐受的情况。
23 例因被蜂蜇(11 例黄蜂,12 例蜜蜂)而出现过敏反应的患者接受了 VIT 治疗。在所有患者中,在开始免疫治疗之前、治疗 1 年以及完成 4-6.5 年免疫治疗(大约在停止治疗 1 年后)时进行 CD63 嗜碱性粒细胞激活试验。然后通过蜇伤挑战试验评估耐受情况。在挑战后 3-6 个月重复进行嗜碱性粒细胞激活试验。
22 名患者蜇伤挑战呈阴性,1 名患者蜇伤挑战呈阳性。在免疫治疗 1 年后,过敏原特异性嗜碱性粒细胞反应保持不变。然而,在免疫治疗后,所有耐受患者的反应(主要是对亚最大浓度 0.1μg/ml 过敏原)均显著且大约四倍下降。这种抑制持续存在,并且不因蜇伤挑战试验而改变。在蜇伤挑战阳性、无耐受的患者中,嗜碱性粒细胞反应没有变化。
我们的结果表明,过敏原特异性嗜碱性粒细胞反应的抑制似乎与完成 VIT 疗程后诱导耐受有关。